What is the clinical evidence from this study?

Study design: Other. Population: Myocardial infarction. Intervention: Icariin vs. Myocardial infarction without icariin treatment. Primary outcome: Cardiac function (Ejection Fraction and Fractional Shortening) and myocardial fibrosis (p=<0.05).

December 19, 2023European journal of medical researchOpen Access

Icariin improves cardiac function and remodeling via the TGF-β1/Smad signaling pathway in rats following myocardial infarction

Q: What are the key findings of this study?

In a rat model of myocardial infarction, administration of icariin significantly improved cardiac function and reduced myocardial fibrosis by suppressing the TGF-β1/Smad signaling pathway.

View Full Paper

Ask AI

Bookmark

Key result

Icariin improves cardiac function and reduces fibrosis in rat MI models by suppressing TGF-β1/Smad signaling.

P<0.05

Why the study?

The study was conducted to assess the effects of icariin on myocardial fibrosis and ventricular remodeling in rats subjected to myocardial infarction.

Does icariin improve cardiac function and prevent remodeling in a rat model of myocardial infarction?

Population

Male Sprague‒Dawley rats subjected to myocardial infarction

Comparison

Icariin (30, 60, or 120 mg/kg/day) vs MI, sham, and control groups

Design

Randomized animal study

Follow-up

90 days

Authors

JJJi Dong JiaYunnan University XZXing-an ZhaoDali University STSiming TaoYunnan University

Discussion

Member takes

Implication

Should not change post-MI practice; hypothesis-generating for icariin in human heart failure trials.

Structured PICO

Does icariin improve cardiac function and prevent remodeling in a rat model of myocardial infarction?

Population

Adult male Sprague-Dawley rats subjected to myocardial infarction via left anterior descending artery ligation, followed for 90 days.

Intervention

Icariin administered at 30 mg/kg/day, 60 mg/kg/day, or 120 mg/kg/day

Comparator

Untreated MI group, sham-operated group, and control group

Outcome

Cardiac function (EF, FS, LVEDD, LVESD) and myocardial fibrosis/remodeling markers at 90 dayssurrogate

Main Result

p-value: p=<0.05

Icariin demonstrates cardioprotective effects in a rat model of post-MI remodeling by improving cardiac function and reducing fibrosis via the TGF-β1/Smad pathway.

Limitations

Short follow-up period precluding observation of long-term changes in cardiac function
Lack of dose-response investigations to determine the most efficacious dosage
Lack of comprehensive long-term safety evaluations
Absence of TTC staining to validate the extent of myocardial infarction
Limited sample size and absence of power calculations
Potential influence of uncontrolled confounding variables

Cite This Study

Jia et al. (2023) studied Myocardial infarction. Icariin vs. Myocardial infarction without icariin treatment was evaluated on Cardiac function (Ejection Fraction and Fractional Shortening) and myocardial fibrosis (p=<0.05). In a rat model of myocardial infarction, administration of icariin significantly improved cardiac function and reduced myocardial fibrosis by suppressing the TGF-β1/Smad signaling pathway.

synapsesocial.com/papers/6aa100f2c0e1046e90f7a7a9 https://doi.org/10.1186/s40001-023-01588-4

View Full Paper

Ask AI

Bookmark

Icariin improves cardiac function and remodeling via the TGF-β1/Smad signaling pathway in rats following myocardial infarction

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Icariin improves cardiac function and remodeling via the TGF-β1/Smad signaling pathway in rats following myocardial infarction

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider